基本信息
浏览量:90
职业迁徙
个人简介
Through his career he was noted for development of targeted cancer treatment capabilities. Specifically, he led the development of the breast cancer treatment Herceptin. The treatment is based on a monoclonal antibody that targets the HER2 protein, which is impacted in aggressive breast cancers. He led the early-stage clinical trial of the drug and led to findings that this targeted treatment along with chemotherapy could extend the lives of patients with HER2 positive breast cancers. He was involved in the clinical development of targeted drugs for cancer including cetuximab, pertuzumab, trastuzumab and lapatinib.[9][10] His research focus extended to the study of drug resistance in some cancers. He also studied drugs that could target tumors stemming from the PI3K mutation.
研究兴趣
论文共 1505 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
crossref(2023)
crossref(2023)
Maurizio Scaltriti,Violeta Serra,Emmanuel Normant,Marta Guzman, Olga Rodriguez, Alice R. Lim,Kelly L. Slocum,Kip A. West, Varenka Rodriguez,Ludmila Prudkin,José Jimenez,Claudia Aura,
crossref(2023)
Violeta Serra,Ben Markman,Maurizio Scaltriti, Pieter J.A. Eichhorn,Vanesa Valero,Marta Guzman, Maria Luisa Botero, Elisabeth Llonch,Francesco Atzori,Serena Di Cosimo,Michel Maira,Carlos Garcia-Echeverria,
crossref(2023)
crossref(2023)
crossref(2023)
Violeta Serra,Ben Markman,Maurizio Scaltriti, Pieter J.A. Eichhorn,Vanesa Valero,Marta Guzman, Maria Luisa Botero, Elisabeth Llonch,Francesco Atzori,Serena Di Cosimo,Michel Maira,Carlos Garcia-Echeverria,
crossref(2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn